HCPCS Level II code J9145 denotes a 10 mg unit of daratumumab, a monoclonal antibody used in oncology and hematology settings. As a drug-specific HCPCS code, J9145 is essential for billing and reimbursement of daratumumab infusions across outpatient infusion centers, hospital outpatient departments, and physician offices. Nationally, accurate use of this code affects payer coverage determinations, prior authorization workflows, and facility revenue capture for high-cost biologic therapies.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, billing benchmarks, and clinical context for use of daratumumab, including how unit-based billing translates to infusion encounters and dose calculation. Readers will find concise benchmarks for per-unit billing, common billing considerations for infusion settings, and an overview of policy updates that influence utilization and prior authorization. Where input data is not provided, the report notes missing elements. This summary serves clinicians, billing professionals, and policy analysts seeking a national perspective on billing practices and administrative considerations for daratumumab using HCPCS Level II code J9145.